Shan Zheng-Zheng, Chen Pei-Nan, Wang Feng, Wang Jun, Fan Qing-Xia
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Department of Oncology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Oncol Lett. 2017 Sep;14(3):2859-2863. doi: 10.3892/ol.2017.6526. Epub 2017 Jul 6.
The phosphorylated epidermal growth factor receptor (P-EGFR) and phosphorylated Akt (P-Akt) protein in esophageal squamous cell carcinoma (ESCC) were studied, and its significance in clinical prognosis of patients was assessed. The expression of P-EGFR and P-Akt protein in 83 cases of ESCC and 83 normal esophageal tissues was determined by immunohistochemical staining. Log-rank test and correlation analysis were used to analyze the prognosis of ESCC. The positive expression of P-EGFR in ESCC was 88% (73/83 cases) compared with 41% in normal esophageal mucosa (34/83 cases) (P<0.05). The rate of P-Akt protein expression in ESCC was 90.4% (75/83 cases), compared with 27.7% seen in normal esophageal mucosa (23/83 cases) (P<0.05). The expression of P-EGFR and P-Akt protein was positively correlated with lymph node metastasis and degree of differentiation (P<0.05) irrespective of sex, age, tumor diameter and TNM stage (P>0.05). The expression of P-EGFR was positively correlated with that of P-Akt protein (r=0.674, P<0.01). P-EGFR expression was negatively correlated with survival time of patients with ESCC (r=-0.526, P<0.01). The Kaplan-Meier survival curves showed that the cumulative survival rate of P-EGFR-positive cases was significantly lower than that of the P-EGFR-negative cases (P<0.01). The expression of P-Akt was negatively correlated with survival in patients with ESCC (r=-0.473, P<0.01). The Kaplan-Meier survival curves showed that the cumulative survival rate of the P-Akt-positive cases was significantly lower than that of the P-Akt-negative cases (P<0.01). In conclusion, P-EGFR and P-Akt protein expression is closely related to the incidence of ESCC and mediates the development of invasive cancer and metastasis. It is used to determine the prognosis of ESCC, and may represent a new therapeutic target for the disease.
研究了食管鳞状细胞癌（ESCC）中磷酸化表皮生长因子受体（P-EGFR）和磷酸化Akt（P-Akt）蛋白，并评估了其在患者临床预后中的意义。采用免疫组织化学染色法检测83例ESCC组织和83例正常食管组织中P-EGFR和P-Akt蛋白的表达。采用对数秩检验和相关性分析来分析ESCC的预后。ESCC中P-EGFR的阳性表达率为88%（73/83例），而正常食管黏膜中为41%（34/83例）（P<0.05）。ESCC中P-Akt蛋白表达率为90.4%（75/83例），正常食管黏膜中为27.7%（23/83例）（P<0.05）。P-EGFR和P-Akt蛋白的表达与淋巴结转移及分化程度呈正相关（P<0.05），与性别、年龄、肿瘤直径及TNM分期无关（P>0.05）。P-EGFR的表达与P-Akt蛋白的表达呈正相关（r=0.674，P<0.01）。P-EGFR表达与ESCC患者的生存时间呈负相关（r=-0.526，P<0.01）。Kaplan-Meier生存曲线显示，P-EGFR阳性病例的累积生存率显著低于P-EGFR阴性病例（P<0.01）。P-Akt的表达与ESCC患者的生存呈负相关（r=-0.473，P<0.01）。Kaplan-Meier生存曲线显示，P-Akt阳性病例的累积生存率显著低于P-Akt阴性病例（P<0.01）。总之，P-EGFR和P-Akt蛋白表达与ESCC的发生密切相关，并介导浸润性癌的发展和转移。它可用于判断ESCC的预后，可能是该疾病新的治疗靶点。
